Could ETQ's share price be soon to benefit from their developments with the new UVGI Nightingale Mobile Air Filtration Product.

New UVGI air filtration product

In November 2002, the ETQ announced its new Nightingale UVGI air filtration product, to be produced by a new joint-venture company, UVGI Systems Limited, owned 55% by the Group and 45% by Suvair Limited. This rapid response mobile air filtration unit is capable of killing the MRSA super bug and other airborne pathogens.

The UVGI unit has widespread application where there is need to keep
air free of dangerous live bacteria, viruses, and fungal spores, including
hospitals, schools, cruise liners, aircraft, food processing, and military
applications.

The UVGI unit uses a high intensity Ultra Violet Germicidal Irradiation ('UVGI')
filter, which has been designed to control harmful and dangerous airborne
pathogens, such as Anthrax, Tuberculosis, and Staphylococcus aureus, the
causative agent in MRSA. The filtration system is combined with use of high
intensity Ultra Violet light, which inactivates micro organisms by disrupting
their DNA structure.

Tests of a prototype at the Defence Science Technology Laboratory ('Dstl') at
Porton Down, the centre for excellence for the Ministry of Defence, showed that
the UVGI unit captured and/or destroyed more than 99.9% of Bacillus subtilis
spores, a simulant for Anthrax bacteria.

Since November, second generation units have been developed, which will go on
applications testing at an NHS Trust Hospital in December 2003, following
building completion of its new haematology unit. It is also anticipated the
UVGI unit will shortly go on laboratory testing in the United States with
contractors nominated by the Department of Homeland Security.

Concern seems to be hotting up on the T.V. news that the MRSA super bug is still killing and disabling people visiting or as patients in NH Trust hospitals. It would be surprising if NH Trust hospital do not notice and Buy this product before they get to many expensive law suits for compensation claims.

Definitely a stock that could soon be heading north. Worth buying in but DYOR

L.

RELATED NEWS LINKS

Sky News Sun 28th Sept 03 - NEW ANTIBIOTICS WARNING
BBC World News Thurs 4th December 03 - Hospital infections: Case studies
BBC World News Fri 5th Dec 03 - 'Superbug' crackdown is launched
BBC World News Monday 22nd Dec 03 - Superbugs lurk in intensive care
Sky News Sun 14th Dec 03 - SUPERBUG CARRIED BY PETS
BBC World News Thurs 26th Feb 04 - Superbug deaths increase 15-fold
BBC World News Mon 22nd March 04 - MRSA superbug hits more children
BBC World News Fri 2nd April 04 - Superbug outbreak in cardiac ward
BBC World News Thurs 8th April 04 - NHS faces superbug legal claims
BBC World News Sun 6th June 04 - Government 'complacent' over MRSA
BBC World News Fri 18th June 04 - Superbug deaths 'set to double'
BBC World News Thurs 1st July 04 - Holland's tough line combats MRSA
BBC World News Thurs 1st July 04 - Overcrowded hospitals breed MRSA
ITV.com Fri 9th July 04 - Mother's MRSA nightmare
ITV.com Fri 9th July 04 - 'MRSA superbug has done this to me'
ITV.com Fri 9th July 04 - Precautions you can take against MRSA
Sky News Sun 11th July 04 - WAR DECLARED ON MRSA
BBC UK News Mon 12th July 04 - Drive to fight hospital superbugs

Hi Sue i have not bought her yet but i read your posts, could you explain a little more about watching the offer if you dont have level 2?

Hi John, the offer price gives you a better indication (see my earlier post). For example, today the T10 holders had their settlement due which the market makers are aware. Hence the market makers knew they would have to sell out and hence lowered the bid price and made the spread at 1 pence which is the maximum. Now they did not bring the offer price down right until ten minutes before close when they tried to panic some into selling and even they were still offering a premium of 0.25 pence on the bid all day for the third trading in a row even though they could have done without that. WINTERFLOODS who is one of the market makers is definetely upto something here, they have been paying a premium on the bid, the premium was 0.27 pence first thing this morning, and they have been filling the large buy orders that came through last week (look at the trades over the last ten trading days). It failed, and L2 closed at its strongest at 3 v 1 so expect a blue day tomorrow. They still not get any sells and I think most of them decided to keep hold of their stock by making the purchase.

Look at the trades on 2 August 2004 and 6 August 2004 for clues to my other posts. It would be a good idea for you to read through my post from when I first bought in at 4.95 pence and how things have developed since then. It will give you a further insight into the ETQ as well.

The chart may not be very pretty yet but then again it was worse when I first got in at 4.95 pence. Snip posted an investtech post about a falling trend at the time but now I can post an Investtech post about a rising trend.

The market makers always play about with the bid price, they are reluctant to bring the offer price down as this stock is on many radars an on each time the buys come in again when they do decide to that.

If you want to buy these with no risk at all then wait for the next news release.

Thanks Sue very well explained, i now see what you mean.

Checked out the ETQ website and found the following two links regarding NQ distribution of ETQ UVGI products. Well worth a look! Clearly the range of UV air filtration products available is far more extensive having just seen the one picture of the Nightingale Unit from the ETQ website.

The links are:

http://www.energytechniqueplc.co.uk/pdfs/UVGI/NQ500.pdf


and

http://www.energytechniqueplc.co.uk/pdfs/UVGI/NQclarifier.pdf


( These links to NQ distributed products are from the ETQ UVGI website page at
http://www.energytechniqueplc.co.uk/Pages/UVGIPages/UVGI_home.html )


It seems highly likely to me that NQ will have successfully sold some of these products by now. I guess we will find out before too long now.

Drug-resistant superbug threatens to break out of hospitals
15 August 2004
By EMILY WATT

Virulent new strains of the MRSA superbug have scientists worried it may soon burst through hospital doors and spread into the community.


A new strain that spreads by skin contact is infecting thousands of people across the globe. The bug has been in New Zealand communities for several years, but scientists say overseas trends suggest it may be becoming more dangerous.

MRSA is a form of staphylococcus, a bacteria found in the noses of one in three healthy New Zealanders, which can cause infections when it breaks through the skin. These can be hard to treat due to MRSA's resistance to antibiotics.

Until now, its danger has been confined to hospitals, where the bug can cause life-threatening infections among the sick and elderly.

Reported MRSA infections have rocketed by 2000 per cent in New Zealand in the past 10 years. Last year, the bug was found in 6168 New Zealanders, 2016 of whom had a strain resistant to more than two antibiotics.

Some hospitals have recently reduced their rates of MRSA through more stringent isolation measures, but scientists are worried that if the hardier bugs spread outside the hospital, there may be no way of controlling them.

NZ Diagnostics microbiologist Richard Doehring said the new strain was more virulent, could spread more easily, and may develop resistance to other drugs. "It is a more highly evolved pathogen," he said.

The infection is spreading rapidly in America and Doehring said the same could happen here.

But other scientists point out the bug has been in New Zealand for years and caused few problems. Chairman of the Health Ministry's antibiotic advisory group, David Holland, said healthy people remained unlikely to fall ill from MRSA and those affected usually had an illness or wound that made them susceptible to infection.

So far the community-based MRSA remained treatable with common antibiotics, but Holland said it was possible the bugs could pick up more resistance genes.

The bacteria can exchange genetic material and transfer resistance on to other bugs without the antibiotic being present.

Holland said the number of drugs available to treat the bugs was running out. "My colleagues are now facing an onslaught. In the long term we're going to have to deal with more of these organisms. Our job is to try to delay it as long as possible."

Holland said more had to be done to restrict the use of antibiotic use in humans and animals.

Southern Community Laboratory scientist John Aitken said the new bacteria were worrying. Once they spread through the community, there was no telling what cross-resistance they could pick up. "The bugs are getting cleverer," he said.

Aitken, Holland and Doehring called for better monitoring of antibiotic resistant bacteria to better understand and prevent the spread of infection. Aitken said not enough was known about the rates of antibiotic resistance in New Zealand. While MRSA rates were recorded, other bugs were emerging that were probably more prevalent but virtually unknown as there was no surveillance. "We're seeing these new things coming out and have no idea where they're coming from.

"We declared war on bacteria when we chucked antibiotics at them but we've only succeeded in annoying them. And when something's annoyed, it comes back at you. We've started the ball rolling and it's up to the bugs now."

Good buy has just come through for 112,143 shares at 6.74 pence. We have gone blue now as well.
My earlier post, see the game WINS were playing. It took one 100K buy to move them off the offer and back onto the bid.

Level 2 at 4 v 4 now.

Another good buy for 100,000 shares has just been reported at 7.00 pence. Re : one of my earlier posts, that the sells that come are miniscule and the buys that come are large.

Level 2 still at 4 v 4, all MM's on the same prices.

Another large buy filled today : 250,000 buy reported just now as delayed at 6.75 pence.

MLSB or WINS filled that buy order today. WINS logged ten minutes after EVO and SCAP today who logged off straight after the market close. Twenty minutes now since the market closed and MLSB are still open.
At close the online buy price was 7.15 pence, and in the morning it was 6.74 pence, in between the 250,000 buy order was put through.
As I always say the sells that come are always miniscule and the buys that come are large.

Sue, do you get all that information from level 2.

Yes John and because I have been looking at every single thing for the last three weeks. Hence I kept stating in my previous post sometimes that something good is brewing here and there is not much point just looking at the charts.

It was MLSB or WINS who filled the 250K buy. Look at the trades for the last week or so, they have been more larger buys that have come through like this one whereas even the sells which were few were miniscule.

One of the market makers MLSB are still open, twenty-five minutes after market close.

Forty minutes after market close and MLSB are still open.

MLSB have just logged off now, 45 minutes after market close.
Any more larger buys will not come through today but tomorrow now as trades over 150,000 shares are delayed in reporting by 1 hour.

Are you saying they stayed open to try and obtain more stock??

It's begining to look like a coiled spring, I may dip in for a few more pre the w/e.

SW

Lots of activity pre-market on Level 2 this morning with the price opening at 6.50-7.00 pence, normal spread restored (the price closed at 6.25-7.25 pence yesterday). WINS are on the new bid of 6.50 pence.
Level 2 at 1 v 1, 6.50-7.00 pence.

Regional news

Superbug timebomb Aug 17 2004

By Helen Clarke, Liverpool Echo

THE deadly superbug MRSA is a ticking timebomb on hospital wards and legal experts warn an explosion of compensation claims could leave the NHS facing massive legal bills.

Liverpool lawyer Ian Cohen, from Goodman's Solicitors which specialises in clinical negligence cases, says hospitals must find a way of controlling the superbug or they will have to foot huge bills from patients who take legal action.

Full article here: http://icliverpool.icnetwork.co.uk/0100news/0100regionalnews/tm_objectid=14541624%26method=full%26siteid=50061%26page=1%26headline=superbug%2dtimebomb-name_page.html

WINS moved down to 6.25 pence on the bid, joining MLSB and SCAP. Level 2 is very positive now at 3 v 1.

Still think more larger buys will be coming again hence the price is not moving at the moment. No sellers at 6.50 pence for WINS so trying out a lower bid. WINS and MLSB upto something. Keep an eye out again for any larger buys again at 6.75 or 7.00 pence later today.

Small buys trickling in, as usual no sellers about at these prices. Level 2 still very positive at 3 v 1.

Last batch of T10 traders from 6 August when the NHS RNS was announced have to settle tomorrow, hence 3 MMs sat on the 6.25 pence bid, why pay them more when the T10s have to close their positions.

Level 2 closed very positive at 3 v 1.


Their presentation to the NHS is to try and get the message across to the NHS of the effectiveness of the Nightingale system which the NHS need to include along with other measures which they need to use to prevent the MRSA problems.As the MRSA problems can be overcome through tackling cleaniness in many ways the NHS need to include as many methods as possible as only one method will not prevent the problem totally.

"The Nightingale technology has been used by hospitals internationally and two units have recently been acquired by North Hampshire Hospital in Basingstoke. Ian De Bruin, Project Director of the Estates Department for the hospital explains how they are currently being used: "North Hampshire currently has two Nightingale systems, one of which is used in the haematology unit, in the area where chemotherapy is performed and where immuno-compromised chemotherapy patients are present. The second is currently kept mobile and may be used in any part of the hospital. We plan to later move the units and use them permanently in the new isolation rooms of the haematology and oncology units at NHH, which are currently under construction.
The systems were picked up as a preventative measure for immunocompromised
patients, to keep their areas as clean as they can possibly be."

for more info see http://www.energytechniqueplc.co.uk/pdfs/UVGI/case%20study2.pdf
It's very encouraging to see that this (NHS) hospital is already planning to retain these units and "use them permanently in the new isolation rooms of the haematology and oncology units at NHH".
Other NHS hospitals are very likely to follow suit in due course in my opinion, it's just a matter of time.

More US sales may follow suit as well :

NQ has been granted a period of exclusivity to 30 September 2004, to enable it
to explore opportunities for marketing the Nightingale unit in the US and
Canadian markets. The Nightingale was exhibited by NQ at a commercial trade
show in the USA in June where interest was very encouraging. The initial sale
in the USA of product using Nightingale technology was achieved in July 2004 to
the Northwest Hospital Center in Randallstown, Maryland.

Hampshire Business South :

Technology - We have the weapon to fight superbug

A HAMPSHIRE company claims to have developed a lifesaving weapon in the fight against the lethal MRSA superbug.

But bosses of Energy Technique Plc say no one in the NHS is interested, despite its potential to prevent heartache for families across the south.

They claim the innovative 6,000 ultraviolet light device will destroy the killer bug but NHS money-men have pleaded poverty, although their American counterparts snapped it up.

The superbug hit the headlines earlier this week when new government figures showed 300,000 cases last year, more than three times as many as initially feared.

As reported in the Daily Echo this week, the number of hospital-acquired MRSA infections at Southampton University Hospitals NHS Trust rose from 53 cases in 2002-03 to 62 in 2003-04 up 17 per cent.

Experts calculate hospital infections kill up to 5,000 people each year in the UK with Methicillin Resistant Staphylococcus Aureus (MRSA) a prime cause.

Called the NightingaleR Unit, the UV device passed tests at Basingstokes North Hampshire Hospital.

The hospitals Ian De Bruin said: The UVGI systems appear capable of dealing with many airborne pathogens on a regular or emergency basis, which is certainly important when dealing with patients with weakened or non-existent immune systems.

The system is an easily serviceable piece of kit, and you dont need to do major intervention in the room with it being moveable.

Leigh Stimpson, group managing director of the former Southampton company which employs 120 people, is disappointed by the NHS response. He said: It is very sad that this sophisticated equipment, which is on sale to the NHS, has gone first to North America.

It is costing the NHS 1 billion a year to control MRSA, and instead of spending money on trying to prevent it in the first place, it is being used to try and deal with it after it has got into hospitals.

A Department of Health spokesman said it was up to trusts to decided if a product like this was suitable.

http://www.nqsouthern.com/digitalpublication/digitalpublications/index.cfm?dpid=144&section_id=1122&article_id=2550